Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Radhika Walling"'
Autor:
Jue Wang, Amir Mortazavi, George Philips, G. Kenneth Haines, Saby George, Joel Picus, Qianqian Zhao, Matthew I. Milowsky, Mohamad Kassar, Daniel M. Geynisman, Mark D. Fleming, Long H. Dang, Noah M. Hahn, Matthew D. Galsky, Robert S. Alter, Menggang Yu, David I. Quinn, Shilpa Gupta, Nancy B. Davis, Sumanta K. Pal, Sumati Gupta, Radhika Walling
Publikováno v:
J Clin Oncol
PURPOSE Platinum-based chemotherapy for first-line treatment of metastatic urothelial cancer is typically administered for a fixed duration followed by observation until progression. “Switch maintenance” therapy with PD-1 blockade at the time of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218a09be88ba4225b90906f5a81a40ca
https://doi.org/10.1200/jco.19.03091
https://doi.org/10.1200/jco.19.03091
Autor:
Jason Brown, Hristos Z. Kaimakliotis, William Kevin Kelly, Vikki Ammons, Joel Picus, Radhika Walling, Neda Hashemi-Sadraei, Pingfu Fu, Seunghee P Margevicius, Nabil Adra, Jorge A. Garcia, Rana R. McKay, Christopher J. Hoimes
Publikováno v:
Journal of Clinical Oncology. 41:448-448
448 Background: Immune checkpoint inhibition (ICI) is a standard of care therapy in metastatic urothelial carcinoma (mUC) but its role in the muscle-invasive setting remains unclear. Prior neoadjuvant ICI studies have demonstrated promising antitumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20b74200e52d7d7edb9b6d89bdc80c22
https://doi.org/10.1200/jco.2023.41.6_suppl.448
https://doi.org/10.1200/jco.2023.41.6_suppl.448
Autor:
Bryan P Schneider, Guanglong Jiang, Tarah J Ballinger, Fei Shen, Christopher Chitambar, Rita Nanda, Carla Falkson, Filipa C Lynce, Christopher Gallagher, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Karen Daily, Reshma Mahtani, Michael A Thompson, Robert Graham, Maureen E Cooper, Dean C Pavlick, Lee A Albacker, Jeffery Gregg, Jeffery P Solzak, Yu-Hsiang Chen, Casey L Bales, Erica Cantor, Bradley A Hancock, Nawal Kassem, Paul Helft, Bert O'Neil, Anna Maria Storniolo, Sunil Badve, Kathy D Miller, Milan Radovich
Publikováno v:
Cancer Research. 82:PD9-10
Purpose: Patients with triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting improved outcomes with capecitabine. Targeted agents have demonstrated acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b6e07aa59291a5b928144d855484380
https://doi.org/10.1158/1538-7445.sabcs21-pd9-10
https://doi.org/10.1158/1538-7445.sabcs21-pd9-10
Autor:
Rita Nanda, Claudine Isaacs, Bradley A. Hancock, Reshma Mahtani, Carla I. Falkson, Casey Bales, Michael A. Thompson, Kathy D. Miller, Maureen Cooper, Anna Maria Storniolo, Lee A. Albacker, Bryan P. Schneider, Tarah J. Ballinger, Marcelo Blaya, Guanglong Jiang, Yuan Zhong, Milan Radovich, Elisavet Paplomata, Chun Li Chang, Dean Pavlick, Sunil Badve, Erica Cantor, Christopher R. Chitambar, Yu-Hsiang Chen, Robert Graham, Cagri A. Savran, Jeffrey P. Solzak, Karen Daily, Radhika Walling, Christopher Gallagher, Filipa Lynce, Jeffrey P. Gregg, Fei Shen
Publikováno v:
JAMA oncology. 6(9)
Importance A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad2db3de4eac108f9c2d1726bb95c97
https://pubmed.ncbi.nlm.nih.gov/32644099
https://pubmed.ncbi.nlm.nih.gov/32644099
Autor:
Lee Ponsky, Michael O. Koch, Clint Cary, Radhika Walling, Robert Abouassaly, Edouard J. Trabulsi, Hristos Z. Kaimakliotis, Costantine Albany, Jean H. Hoffman-Censits, Nabil Adra, Matthew M. Cooney, Joel Picus, J. Luke Godwin, Pingfu Fu, Ginu Xavier, W. Kevin Kelly, Mark D. Fleming, Ariel Ann Nelson, Christopher J. Hoimes
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:We sought to assess if pembrolizumab (pembro) improves the pathologic response rate in locally advanced urothelial carcinoma (UC) when combined with gemcitabine (G) and ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac27b1137d745c744dfba6390af7f0e4
https://doi.org/10.1097/01.ju.0000556959.45525.89
https://doi.org/10.1097/01.ju.0000556959.45525.89
Autor:
Hristos Z. Kaimakliotis, Gordon Goolamier, Adam Calaway, Edouard J. Trabulsi, Michael O. Koch, Zachary L. Smith, Mark D. Fleming, Pingfu Fu, Nabil Adra, L. Ponsky, Robert Abouassaly, Clint Cary, William Kevin Kelly, Jean H. Hoffman-Censits, Radhika Walling, Cheryl Eitman, Christopher J. Hoimes, Joel Picus
Publikováno v:
Journal of Clinical Oncology. 38:5047-5047
5047 Background: Patients (pts) with laUC who are C-eligible for N- therapy may benefit from combination chemo-immunotherapy. Cohort 1 (C1) of the GU14-188 trial is a phase 1b/2 trial designed to assess the tolerability and efficacy of N- gemcitabine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02bf6d54da2d20c7f2532ad6c14348e2
https://doi.org/10.1200/jco.2020.38.15_suppl.5047
https://doi.org/10.1200/jco.2020.38.15_suppl.5047
Autor:
L. Ponsky, William Kevin Kelly, Hristos Z. Kaimakliotis, Edouard J. Trabulsi, Adam Calaway, Timothy A. Masterson, Richard C. Lauer, Pingfu Fu, Joel Picus, Nabil Adra, Christopher J. Hoimes, Michael O. Koch, Cheryl Eitman, Zachary L. Smith, Gordon Goolamier, Radhika Walling, Elizabeth Sonderman
Publikováno v:
Journal of Clinical Oncology. 38:5019-5019
5019 Background: Patients (pts) with laUC who are C-ineligible have inferior survival compared to counterparts who receive C based N-therapy and have a pathologic response at radical cystectomy (RC). Cohort 2 (C2) of the GU14-188 trial is designed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4561f02093a06797511d2434fecb7463
https://doi.org/10.1200/jco.2020.38.15_suppl.5019
https://doi.org/10.1200/jco.2020.38.15_suppl.5019
Autor:
Reshma Mahtani, Maureen Cooper, Christopher Gallagher, Filipa Lynce, Bradley A. Hancock, Casey Bales, Robert Graham, Tarah J. Ballinger, Elisavet Paplomata, Kathy D. Miller, Guanglong Jiang, Rita Nanda, Claudine Isaacs, Milan Radovich, Fei Shen, Radhika Walling, Marcelo Blaya, Erica Cantor, Karen Daily, Christopher R. Chitambar, Jeffrey P. Gregg, Bryan P. Schneider, Dean Pavlick, Sunil Badve, Carla I. Falkson, Anna Maria Storniolo, Lee A. Albacker, Michael A. Thompson
Publikováno v:
Cancer Research. 80:GS5-02
Background: A significant proportion of patients with early-stage TNBC are treated with neoadjuvant chemotherapy (NAC). Sequencing of ctDNA after surgery can be used to detect minimal residual disease and predict which patients may experience clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c086f4f5862bf479c523dc7695e66a5
https://doi.org/10.1158/1538-7445.sabcs19-gs5-02
https://doi.org/10.1158/1538-7445.sabcs19-gs5-02
Autor:
Robin Zon, Ebenezer A. Kio, Karen L. Reckamp, Goetz H. Kloecker, Nasser H. Hanna, Sandra K. Althouse, M. Williamson, C. Yeon, B. Adesunloye, Salma K. Jabbour, G. Durm, Ryan D. Gentzler, Shadia I. Jalal, Wael A. Harb, Marianna Koczywas, Radhika Walling, Robert M. Langdon, Ahad Ali Sadiq
Publikováno v:
Journal of Thoracic Oncology. 14:S627
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fd8160ed3e24c1ada44a1fa7aba85cb
https://doi.org/10.1016/j.jtho.2019.08.1321
https://doi.org/10.1016/j.jtho.2019.08.1321
Autor:
Matthew D. Galsky, Joel Picus, David I. Quinn, David D. Chism, Sumanta K. Pal, Sumati Gupta, Daniel M. Geynisman, Robert S. Alter, Radhika Walling, Menggang Yu, Erwin L. Robin, George Philips, Amir Mortazavi, Matthew I. Milowsky, Jue Wang, Mark D. Fleming, Long H. Dang, Noah M. Hahn, Saby George, Shilpa Gupta
Publikováno v:
Journal of Clinical Oncology. 37:4504-4504
4504 Background: Platinum-based chemotherapy for 1st-line treatment of pts with metastatic urothelial cancer (mUC) is typically administered for a fixed duration followed by observation until recurrence. PD-1 blockade with pembro improves survival of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e03e3e4d82a535a7c655333b2e427fc4
https://doi.org/10.1200/jco.2019.37.15_suppl.4504
https://doi.org/10.1200/jco.2019.37.15_suppl.4504